Alpha 2.0
Login Register
» Articles » PMID: 39893377

Treating Chronic Kidney Disease in Danish Primary Care: Results from the Observational ATLAS Study

Overview
Journal BMC Prim Care
Date 2025 Feb 1
PMID 39893377
Authors
Morten Lindhardt
Soren Tang Knudsen
Thomas Saxild
Morten Charles
Rikke Borg
Affiliations
Soon will be listed here.
Abstract

Objectives: To describe the clinical characteristics, comorbidity, and medical treatment in a primary care population with chronic kidney disease (CKD). Additionally, to investigate how primary care physicians (PCPs) diagnose, manage and treat impaired kidney function, including uptake of cardio-renoprotective renin-angiotensin-aldosterone system inhibitors (RAASis) and sodium glucose co-transporter 2 inhibitors (SGLT2is).

Design: An observational study of CKD prevalence, treatment patterns and comorbidities in primary care based on patient record data combined with a questionnaire on diagnosis, management and treatment of impaired kidney function in a real-world, primary care setting.

Setting: In all 128 primary care clinics in Denmark of 211 randomly invited and a quetionnaire completed by 125/128 participating PCPs.

Methods: A computerized selection identified 12 random individuals with CKD per clinic with ≥ 2 measurements of eGFR < 60 mL/min/1.73 m or UACR > 30 mg/g within two years (N = 1 497). Pre-specified data collected from individual electronic health records included demographics, clinical variables, comorbidities, and relevant prescribed medications.

Results: Of the CKD study population (N = 1 497), 80% had hypertension, 32% diabetes (DM), 13% heart failure (HF), 59% no DM/HF. ACEis/ARBs were prescribed to 65%, statins to 56%, SGTL2is to 14%, and MRAs to 8% of all individuals. Treatment patterns differed between individuals with varying comorbidities, e.g., ACEis/ARBs usage was higher in DM (76%) or HF (74%) vs. no DM/HF (58%), as was statin usage (76% in DM vs. 45% in no DM/HF). SGTL2i usage in no DM/HF was low. Most PCPs identified CKD using eGFR < 60 mL/min/1.73 m (62%) or UACR > 30 mg/g (58%) and 62% reported initiating treatment to retard kidney function decline.

Conclusions: Despite good PCP awareness and wish to use relevant guidelines, a gap exists in implementation of cardio-renoprotective treatment, especially in individuals without DM/HF. This offers an opportunity for clear recommendations to PCPs to optimize early cardio-renal protection in individuals with CKD.

References
1.
Persson F, Charles M, Povlsen J, Knudsen S . Improving frequency of urinary albumin testing in type 2 diabetes in primary care - An analysis of cross-sectional studies in Denmark. Prim Care Diabetes. 2021; 15(6):1007-1011. DOI: 10.1016/j.pcd.2021.07.003. View
2.
Tuttle K, Alicic R, Kenrik Duru O, Jones C, Daratha K, Nicholas S . Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry. JAMA Netw Open. 2019; 2(12):e1918169. PMC: 6991307. DOI: 10.1001/jamanetworkopen.2019.18169. View
3.
Rossing K, Jacobsen P, Pietraszek L, Parving H . Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care. 2003; 26(8):2268-74. DOI: 10.2337/diacare.26.8.2268. View
4.
van Mil D, Pouwels X, Heerspink H, Gansevoort R . Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps. Clin Kidney J. 2024; 17(1):sfad254. PMC: 10783263. DOI: 10.1093/ckj/sfad254. View
5.
Martinez F, Serenelli M, Nicolau J, Petrie M, Chiang C, Tereshchenko S . Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. 2019; 141(2):100-111. DOI: 10.1161/CIRCULATIONAHA.119.044133. View